Asthma control in severe asthmatics under treatment with omalizumab: a cross-sectional observational study in Italy.

[1]  B. Chipps,et al.  Impact of asthma exacerbations and asthma triggers on asthma-related quality of life in patients with severe or difficult-to-treat asthma. , 2014, The journal of allergy and clinical immunology. In practice.

[2]  G. Braunstahl,et al.  The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma. , 2013, Respiratory medicine.

[3]  F. Percival,et al.  Effectiveness of Omalizumab in Severe Allergic Asthma: A Retrospective UK Real-World Study , 2013, The Journal of asthma : official journal of the Association for the Care of Asthma.

[4]  J. Salleron,et al.  Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey , 2013, European Respiratory Journal.

[5]  M. Eisner,et al.  Population-Based Efficacy Modeling of Omalizumab in Patients with Severe Allergic Asthma Inadequately Controlled with Standard Therapy , 2013, The AAPS Journal.

[6]  J. Benichou,et al.  Does omalizumab make a difference to the real-life treatment of asthma exacerbations?: Results from a large cohort of patients with severe uncontrolled asthma. , 2013, Chest.

[7]  Hubert C. Chen,et al.  Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab. , 2013, Respiratory medicine.

[8]  E. Bleecker,et al.  Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. , 2012, The Journal of allergy and clinical immunology.

[9]  M. Duh,et al.  Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma. , 2012, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[10]  P. Paggiaro,et al.  Asthma Control Test (ACT): Comparison with Clinical, Functional, and Biological Markers of Asthma Control , 2012, The Journal of asthma : official journal of the Association for the Care of Asthma.

[11]  J. Farrar,et al.  Omalizumab and asthma control in patients with moderate-to-severe allergic asthma: a 6-year pragmatic data review. , 2012, Allergy and asthma proceedings.

[12]  N. Tzanakis,et al.  Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience. , 2012, Pulmonary pharmacology & therapeutics.

[13]  W. Busse,et al.  Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy , 2011, Annals of Internal Medicine.

[14]  M. Cazzola,et al.  Italian real-life experience of omalizumab. , 2010, Respiratory medicine.

[15]  L. Dupont,et al.  "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. , 2009, Respiratory medicine.

[16]  S. Korn,et al.  Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. , 2009, Respiratory medicine.

[17]  K. Chung,et al.  Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. , 2008, Respiratory medicine.

[18]  K. Rabe,et al.  Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma , 2008, European Respiratory Journal.

[19]  Mike Thomas,et al.  Cluster analysis and clinical asthma phenotypes. , 2008, American journal of respiratory and critical care medicine.

[20]  S. Sullivan,et al.  An evaluation of the cost‐effectiveness of omalizumab for the treatment of severe allergic asthma , 2008, Allergy.

[21]  A. Didier,et al.  Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. , 2008, Respiratory medicine.

[22]  A. Zwinderman,et al.  Risk factors of frequent exacerbations in difficult-to-treat asthma , 2005, European Respiratory Journal.

[23]  J. Bousquet,et al.  Anti‐immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti‐inflammatory activity and clinical efficacy , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[24]  J Bousquet,et al.  Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE , 2005, Allergy.

[25]  C. Bucca,et al.  Asthma severity and medical resource utilisation , 2004, European Respiratory Journal.

[26]  Bénédicte Leynaert,et al.  Sensitisation to airborne moulds and severity of asthma: cross sectional study from European Community respiratory health survey , 2002, BMJ : British Medical Journal.

[27]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[28]  J E Cotes,et al.  Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.